Shirley D’Sa: What Comes After BTK Inhibitors in Waldenström Macroglobulinaemia?
Shirley D’Sa, Professor of Haematology at United KingdomUnited Kingdom, shared on LinkedIn about a recent article she and her colleagues co-authored, published in Hematology Reports, adding:
”Treatment options following BTK inhibitor failure in Waldenström macroglobulinaemia (WM) remain an important unmet need in our field.
Our recently published article explores the role of bortezomib-based therapy in patients who have progressed following BTKi treatment, providing valuable real-world evidence in an area where prospective data remain limited.
As the therapeutic landscape of WM continues to evolve—with non-covalent BTK inhibitors, BTK degraders, BCL2 inhibitors, bispecific antibodies and cellular therapies all under investigation—it is important not to overlook the potential utility of established agents such as proteasome inhibitors.
The paper contributes to the growing discussion around treatment sequencing in WM and the question many of us increasingly face in clinical practice: what comes after BTKi?
An interesting read for anyone involved in the care of patients with WM and related IgM disorders.”
Title: Bortezomib in Patients Who Fail BTKi in Waldenström Macroglobulinaemia
Authors: Tahanzaib Khwaja, Nicole Japzon, Simona Gatto, Jindriska Lindsay, Charalampia Kyriakou, Shirley D’Sa
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 10, 2026, 11:25Andreas Glenthøj: New Sickle Cell Trait Data in UpToDate
-
Sep 10, 2026, 10:53A New Era of Hemophilia Screening and Diagnosis in Women and Girls – ISTH
-
Sep 10, 2026, 10:03Investing in Youth, Transforming Hemophilia Care – WFH
-
Sep 10, 2026, 09:51Ronke Oke BEM: 20 Years of Newborn Sickle Cell Screening in England
-
Sep 10, 2026, 09:41Seunghwan Song: Hemlibra and the Science That Changed Hemophilia A Care
-
Sep 10, 2026, 09:20Mark Dawson: A Radical Rethink of Hemophilia Treatment
-
Sep 10, 2026, 07:26Carly Newton: Every Donation Helps Save Lives
-
Sep 10, 2026, 07:152023 ACR/EULAR APS Classification Criteria – APS Foundation of America
-
Sep 10, 2026, 07:03When Platelet Function Matters More Than Platelet Count – Glanzmann’s Research Foundation